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Transferrin saturation versus reticulocyte hemoglobin content of recombinant human erythropoietin (rhEPO) causes
for iron deficiency in Japanese hemodialysis patients. a rapid increase in hematocrit levels, eliminates the need
Background. Iron deficiency is a frequent cause of recombi- for transfusions, and improves the symptoms accompaniednant human erythropoietin (rhEPO)-resistant anemia in hemo-
with anemia in end-stage renal disease or progressivedialysis patients. Both reticulocyte hemoglobin content (CHr)
and transferrin saturation (TSAT) have been proposed as renal failure [1–4]. It is also possible to restore hemato-
markers of iron deficiency, but it is unclear which parameter crit to the normal level if sufficient rhEPO is adminis-
is superior. tered [5]. However, iron deficiency is one of the mostMethods. To compare the efficacy of CHr and TSAT as an
common causes of a suboptimal response to erythropoie-indicator for treatment of iron deficiency, we conducted a sin-
gle-center, open-label, prospective, randomized, controlled tin therapy [6–11]. Gastrointestinal iron absorption is
trial at the Kidney Center in Shinraku-en Hospital of 197 Japa- less than ongoing losses due to loss of blood in the dia-
nese patients on chronic hemodialysis. After 4 weeks of run- lyzer [12] or frequent blood tests, so aggressive manage-in period during which iron supplementation was suspended,
ment of iron deficiency is necessary to treat anemia in100 patients who were randomized to the CHr group received
hemodialysis patients. Indeed, parenteral iron supple-240 mg iron colloid intravenously over 2 weeks when CHr less
than 32.5 pg, and 97 patients who were randomized to the mentation in patients treated with rhEPO, who have
TSAT group received the same doses of iron colloid when insufficient iron stores and even replete iron stores, can
TSAT less than 20%. We measured the rhEPO dose needed to
correct the anemia with decreased mortality and hospi-maintain prestudy hematocrit levels, hematocrit, CHr, TSAT,
talization, improve the quality of life, and reduce theserum ferritin, percentage of hypochromic red blood cells, and
total iron administered. dose of rhEPO [7, 9 –11, 13–16]. The reduction of rhEPO
Results. Sixteen weeks later, 94 patients in the CHr group dose is also economically favorable [10, 11, 14, 17].
and 89 patients in the TSAT group finished the study. The
The serum ferritin and transferrin saturation (TSAT),doses of rhEPO required decreased by 35.8% (4081 to 2629
both reflecting total body iron stores, are commonly usedU/week, P 0.005) in the TSAT group, but not significantly in
the CHr group (4121 to 3606 U/week). Although CHr increased to indicate iron status in hemodialysis patients [17–19].
promptly after the iron administration in both groups, TSAT The National Kidney Foundation-Dialysis Outcomes
increased only in the TSAT group. Quality Initiative (NKF-DOQI) guidelines recommendedConclusions. Although CHr reflects the iron status more
maintaining serum ferritin at or less than 100 ng/mL, orsensitively, TSAT is a better clinical marker for iron supple-
mentation therapy. TSAT at or less than 20% to manage iron deficiency
[8]. However, some papers report these cutoff values as
insufficient to treat “functional iron deficiency,” in which
Anemia is one of the major complications of chronic sufficient iron is not released from the body iron stores
renal failure, especially for patients undergoing chronic to meet an increased request for iron in the red blood
hemodialysis for end-stage renal disease. Administration cell production accelerated by rhEPO administration,
despite a normal or even elevated serum ferritin level
[9, 10, 13, 18–20].Key words: erythropoietin, randomized controlled trial, serum ferritin,
anemia, parenteral iron, chronic hemodialysis. Other markers, such as zinc protoporphyrin [21] or
soluble transferrin receptor [22], have been proposed as
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TSAT [9], and their usefulness as markers of iron defi- before enrollment; and (2) no prior adverse reactions
to parenteral iron. Exclusion criteria were hematologicciency is still controversial [23–25].
Reticulocyte hemoglobin content (CHr) and percent- malignancies, hemolytic anemia, active gastrointestinal
bleeding, acute severe infection (C-reactive protein lessage of hypochromic red blood cells are other indices of
iron status, which reflect the iron status at the level of the than 10 mg/dL), chronic inflammatory disease, aluminum
toxicity, uncontrolled hypertension, or hyperparathyroid-erythrocyte itself [26– 32]. Specifically, CHr is expected
to provide a “snapshot” of functional iron status because ism (intact parathyroid hormone less than 1000 pg/mL).
of the reticulocytes’ short lifespan, and, more recently,
Measurement of hematologic and iron status markersome papers have reported a correlation between CHr
and other indices of iron status in iron deficiency anemia Hematocrit, CHr, percentage of hypochromic red
blood cells, serum iron, unsaturated iron-binding capac-of healthy and chronic hemodialysis patients [26, 29–32].
In the United States and in Europe, CHr less than 26.0 ity (UIBC), and serum ferritin were measured at the
beginning of each hemodialysis therapy twice per month,pg, measured by H*3 hematology analyzer, or CHr less
than 29.0 pg, measured by ADVIA120 (Bayer, Tarry- 3 days after the previous hemodialysis therapy, to deter-
mine the dose of rhEPO or the implementation of intra-town, NY, USA), is used as the indicator of iron defi-
ciency, and several authors reported that CHr increased venous iron therapy. Blood counts and red blood cell
indices were measured by standard automated counterpromptly within a few days after iron supplementation
and was useful as an indicator for iron deficiency [29–32]. methods. CHr (pg) and hypochromic red blood cells
(%), in which the content of hemoglobin was less thanIn Japan, however, only a few studies were conducted
about CHr, and one of these studies reported that the cut- 28 g/dL, were measured by a flow cytometric method
(ADVIA). Serum iron (g/dL) and UIBC (g/dL) wereoff value of CHr to define iron deficiency should be set
by 32.2 pg in Japanese chronic hemodialysis patients (ab- measured by a colorimetric method (7600-020, Hitachi,
Tokyo, Japan). Serum ferritin (ng/mL) was measuredstract; Okano et al, J Jpn Soc Dial Ther 34:1079, 2001).
Little has also been reported on the usefulness of CHr by a chemiluminescence immunoassay method (BN II,
Dade Behring, Marburg, Germany). TSAT (%) was cal-as a target of iron supplement therapy compared to
TSAT or serum ferritin. The aim of the present study culated as serum iron/serum iron plus UIBC.
is to set the cutoff value of CHr and to clarify which
Administration of study medicationparameter, CHr or TSAT, is superior to detect iron defi-
ciency and to reduce the amount of rhEPO required Intravenous iron colloid with chondroitin sulfate (Blu-
tal, Dainippon Pharmaceutical, Tokyo, Japan), 40 mg,without decreasing the hematocrit values in Japanese
chronic hemodialysis patients. was administered three times per week for 2 weeks at
the end of each hemodialysis therapy when CHr was less
than 32.5 pg in the CHr group or TSAT was less than
METHODS
20% in the TSAT group. Participants in both groups
Study design received either epoetin alpha (Espo, Kirin Brewery,
Tokyo, Japan) or epoetin beta (Epogin, Chugai Phar-This single-center, open, intention to treat, random-
ized, controlled clinical trial was performed at the Kidney maceutical, Tokyo, Japan) if needed. The dose of rhEPO
was adjusted as necessary at the measurement of hemato-Center in Shinraku-en Hospital between May 2001 and
September 2001. Patients were randomly assigned in a logic and iron status markers to maintain the hematocrit
between 29.5 and 32.5%. Doses of rhEPO administered1:1 ratio to receive intravenous iron therapy when CHr
was less than 32.5 pg (CHr group), or TSAT was less were categorized as 0, 750, 1500, 2250, 3000, 4500, 6000,
or 9000 U per week and modified as follows: (1) hemato-than 20% (TSAT group), at which time all oral iron
supplementation was discontinued. The protocol was re- crit was less than 26.0%, rhEPO dose was raised by 200%;
(2) hematocrit was equal to or more than 26.0% and lessviewed and approved by the Institutional Review Board
in Shinraku-en Hospital. Written informed consent was than 29.0%, rhEPO dose was raised by 100%; (3) hema-
tocrit was equal to or more than 29.0% and less thanobtained from the participants before enrollment.
29.5%, rhEPO dose was raised by 50%; (4) hematocrit
Patient enrollment was more than 32.5% and less than or equal to 33.0%,
rhEPO dose was reduced by 33%; (5) hematocrit wasPatients 18 years of age or older undergoing chronic
hemodialysis treatment were eligible. The range of the more than 33.0% and less than or equal to 36.0%, rhEPO
dose was reduced by 50%; and (6) hematocrit was moretime patients had been receiving hemodialysis was from
2 months to 26 years. Other eligibility criteria were (1) than 36.0%, administration of rhEPO was suspended.
When the administration of rhEPO had been sus-use of rhEPO doses of 750 to 3000 U administered intra-
venously one to three times per week for anemia man- pended and hematocrit was less than 29.5%, 2250 U per
week of rhEPO was resumed. If the modified rhEPOagement for at least 4 weeks within the last 3 months
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Table 1. Baseline demographic characteristics of patientsdose in accordance with the rule mentioned above did
not apply to any of the categories, the nearest dose in CHr Group TSAT Group
Variable (N  100) (N  97)category was adopted.
Men/women number 61/39 60/37
Age year 57.613.3 61.214.5Outcome measures
Age range year 26–88 27–88
The main outcome of interest was the dose of rhEPO Cause of ESRD number
Chronic glomerulonephritis 62 63required to keep the hematocrit at its baseline level.
Diabetic nephropathy 12 15Secondary outcomes included the difference of the total
Nephrosclerosis 7 8
dose of iron administered or the difference of hemato- Polycystic kidney 2 3
Chronic pyelonephritis 2 3logic and iron status markers between the two groups.
Congenital renal hypoplasty 2 2
Purpura nephritis 2 0Monitoring of adverse events
Membranous nephropathy 2 0
Othersa 9 3All patients receiving study medication were evalu-
Hematocrit % 31.23.3 31.42.9ated for safety. Signs and symptoms were evaluated dur-
CHr pg 33.22.1 33.22.5
ing and after each hemodialysis session, and the incidence Hypochromic red blood cells % 3.94.9 4.55.6
Transferrin saturation % 25.212.0 26.316.0of hospitalization, infections, and deaths was recorded.
Serum ferritin ng/mL 243.2323.4 251.6371.2
TIBC lg/dL 241.947.4 241.147.0Statistical analysis
Intact PTH pg/mL 278.5257.5 244.2234.2
Vitamin D3 doseFor comparisons between two groups at baseline and
Alfacalcidol lg/day 0.370.13 0.320.11after the trial, we used the Student t test for all the
Calcitriol lg/day 0.440.67 0.340.23
subjects except for doses of rhEPO and iron, and the Maxacalcitol lg/day 9.25.2 8.32.9
rhEPO dose U/week 42632982 39692872Mann-Whitney U test for doses of rhEPO and iron.
rhEPO dose range U/week 0–9000 0–9000Comparisons of all the subjects except for doses of
Epoetin alpha number 33 29
rhEPO in each group were performed using repeated Epoetin alpha dose U/week 4591286 46033224
Epoetin alpha dose range U/week 750–9000 0–9000measure one-way analysis of variance (ANOVA), fol-
Epoetin beta number 67 68lowed by Fisher’s protected least significant difference
Epoetin beta dose U/week 41803060 37282693
as a post-hoc test. Comparisons with respect to rhEPO Epoetin beta dose range U/week 0–9000 0–9000
TSAT 20% number 34 37dose in each group were conducted using the Friedman
CHr 32.5 pg number (%) 20 (58.8) 22 (59.5)test, followed by the Wilcoxon signed-rank test with
CHr 32.5 pg number (%) 14 (41.2) 15 (40.5)
Bonferroni correction as a post-hoc test. Comparison of CHr 32.5 pg number 35 32
TSAT 20% number (%) 20 (57.1) 22 (68.8)the number of patients of which TSAT was less than
TSAT 20% number (%) 15 (42.9) 10 (31.2)20%, and CHr was less than 32.5 pg, or CHr was 32.5
Abbreviations are: ESRD, end-stage renal disease; CHr, reticulocyte hemoglo-pg or more, was performed using the Fisher’s exact prob-
bin content; TIBC, total iron binding capacity; PTH, parathyroid hormone;
ability test. A P value 0.05 was considered significant. rhEPO, recombinant human erythropoietin; TSAT, transferrin saturation. All
results are expressed as mean  SD. None of the variables differed significantlyAll statistical calculations were performed using Stat-
between the groups.
View, version 5.0 (SAS Institute Inc., Cary, NC, USA). aRenal tuberculosis, primary amyloidosis, or unknown causes
Role of the funding source
The funding source had no role in the collection, analy-
cantly between either group (Table 1). We had pre-sis, or interpretation of the data or in the decision to
viously verified that there was no difference on the effectsubmit the study for publication.
to promote erythropoiesis between epoetin alpha and
epoetin beta (data not published), so we calculated the
RESULTS average dose of rhEPO without dividing epoetin alpha
Patients and epoetin beta throughout the present study.
Values of CHr and TSAT of all 197 patients wereOf 242 patients who met the study criteria, 197 patients
measured at the enrollment and a weak correlation be-were enrolled and randomly allocated (100 patients in
tween CHr and TSAT was revealed (r  0.580, r2 the CHr group and 97 patients in the TSAT group). The
0.336, P  0.0001, Fig. 1). We defined TSAT of less thangroups did not significantly differ in baseline demo-
20% as indicating iron deficiency according to NKF-graphic characteristics (Table 1). The average doses of
DOQI guidelines [8], and when we set the cutoff valuerhEPO, including epoetin alpha and epoetin beta at the
of CHr at less than 32.5 pg, it had a sensitivity of 59.2%time of enrollment, were 4263 U/week in the CHr group
and a specificity of 62.7% for the diagnosis of iron defi-and 3969 U/week in the TSAT group, a difference of
ciency. When the cutoff values were set at 29.0 pg, 31.57%, which was not significant. The dose and proportion
of epoetin alpha and epoetin beta did not differ signifi- pg, 32.0 pg, or 33.0 pg, sensitivities were 9.9%, 40.8%,
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Hematocrit values in both groups fluctuated during
the study, but no difference of the value was observed
between the two groups and the hematocrit values at
the end of the trial were almost the same as the baseline
values (Table 2).
The amount of total dosage of iron colloid adminis-
tered became significantly higher in the TSAT group
13 weeks after the beginning of intervention and this
tendency continued to the end of the study (Table 2).
Difference of iron status
After 16 weeks of the trial, the value of TSAT in-
Fig. 1. Correlation between transferrin saturation and reticulocyte he- creased significantly in the TSAT group and was signifi-
moglobin content. * y  294  0.191x – 0.001x2; r2  0.336, P  0.0001.
cantly higher than those in the CHr group (P  0.034).
In contrast, no significant increase of TSAT was observed
in the CHr group. The serum ferritin value also increased
dramatically in the TSAT group, and the value was higher52.1%, 69.0%, and specificities were 87.5%, 74.4%,
75.6%, 57.0%, respectively. Considering these data, we by 33.3% than the value in the CHr group at the end of
the study. Two other markers, CHr and hypochromic reddecided on CHr less than 32.5 pg as a proper cutoff value
for indication of intravenous iron therapy in the present blood cells, which indicate iron status at the erythrocyte
level, promptly improved equally from the baseline 4study.
At the enrollment, 13 patients were taking oral iron weeks and 9 weeks, respectively, after the interventional
treatment in both groups. Improvement of CHr was ob-every day and the others were receiving intravenous iron
on an as needed basis when TSAT was less than 20%. served 9 weeks earlier than the significant increase of TSAT
in the TSAT group was first observed in week 13. How-After 4 weeks of run-in period, during which oral and
parenteral iron administration was suspended, 183 pa- ever, no significant differences on the values of CHr and
hypochromic red blood cells were observed between thetients (94 patients in the CHr group and 89 patients in
the TSAT group) completed the entire 16 weeks of study. two groups. In addition, substantial improvement of the
values of CHr and hypochromic red blood cells was notOf the 197 participants, 14 participants (six in the CHr
group and eight in the TSAT group) prematurely discon- observed from week 11 to the end of the trial (Table 2).
Comparison of test variability was measured for CHr,tinued the trial. The reasons for discontinuing the trial
included withdrawn consent (three in the CHr group TSAT, and serum ferritin and was expressed as coeffi-
cient of variation (% CV). CHr had 6.3% of % CV,and four in the TSAT group), deaths (two in the CHr
group and one in the TSAT group), loss of follow-up which was obviously less than that of TSAT (48.9%) or
serum ferritin (130.5%).(one in the CHr group and two in the TSAT group),
and massive bleeding (one in the TSAT group). We reevaluated the sensitivity and the specificity of
CHr for the diagnosis of iron deficiency at the end of
Efficacy the trial. Between the two groups, although specificities
did not differ (66.7% both in the CHr group and in theTable 2 shows the change of the dose of rhEPO admin-
istered to 184 participants who completed the trial. Al- TSAT group), sensitivity was much lower in the CHr
group (23.1% in the CHr group and 57.1% in the TSATthough some significant increase of the rhEPO dose was
observed in the CHr group 4 weeks after the beginning group). Table 3 shows the number of participants who
were diagnosed as iron deficiency by TSAT less thanof intervention, the dose of rhEPO in the TSAT group
significantly decreased from the baseline dose 11 weeks 20% among all the participants. Significantly more parti-
cipants in the CHr group had CHr values higher thanafter the beginning of intervention and this tendency
continued until the end of the trial. The dose of rhEPO 32.5 pg despite the fact that TSAT was less than 20%
(P  0.043) and, consequently, the sensitivity of CHrrequired was significantly lower in the TSAT group com-
pared with those in the CHr group (P  0.05) 11 and 13 lowered only in the CHr group. In contrast, same propor-
tion of patients both in the CHr group and the TSATweeks after the start of the trial. Although the difference
between the two groups was obvious, but not statistically group had a TSAT value less than 20% among the pa-
tients who had CHr less than 32.5 pg (Table 4). Conse-significant at the end of the trial (P  0.10), the dose of
rhEPO required finally decreased from the baseline by quently, when CHr less than 32.5 pg was defined as
indicating iron deficiency, sensitivity of TSAT was the35.6% (4081 to 2629 U/week, P  0.005) in the TSAT
group, but did not decrease significantly in the CHr group same (66.7%) in both CHr group and TSAT group at
the end of the trial.(4121 to 3606 U/week).
Kaneko et al: CHr versus TSAT1090
Table 2. Average values for recombinant human erythropoietin, hematocrit, transferrin saturation, ferritin, reticulocyte hemoglobin content,
hypochromic red blood cells, and total iron
Time rhEPO Hct TSAT Ferritin CHr2 Hypochromic Total iron
period U/week % % ng/mL pg RBC % mg
Baseline
CHr 41212922 31.23.2 25.512.6 234.5307.0 33.22.2 3.74.9 0
TSAT 40813123 31.32.8 25.715.6 257.0453.4 32.82.4 4.15.3 0
Week 2
CHr 45743261 30.1a3.2 26.311.8 259.4296.7 32.7b1.8 4.5b5.7 68.3108.0
TSAT 44243220 30.42.3 25.813.3 289.9405.2 32.71.7 5.1b6.7 91.7117.3
Week 4
CHr 5426a3481 29.5c2.9 28.011.5 285.8c302.5 33.6b1.7 4.15.1 164.8193.6
TSAT 48033325 29.9b1.9 28.213.6 305.5b397.2 33.5c2.2 4.45.4 180.7199.1
Week 6
CHr 44843476 32.1b2.8 27.812.5 285.6c302.0 35.3c2.2 3.74.3 214.1242.1
TSAT 38433092 32.4a2.2 26.512.5 304.8397.5 34.8c2.4 3.83.9 226.5254.2
Week 9
CHr 39573320 31.53.0 28.613.2 269.4b303.4 34.7c1.6 1.9c2.0 232.0268.8
TSAT 30512730 32.1b2.5 28.512.1 323.1a423.7 34.4c2.2 1.8c2.3 283.1297.4
Week 11
CHr 36383276 31.92.9 28.914.3 279.7b298.8 34.6c1.8 1.7c2.0 247.3305.5
TSAT 2528b,d2736 32.4a2.8 28.713.6 331.8a466.7 34.4c1.8 1.7c2.2 315.5312.5
Week 13
CHr 35353310 31.42.9 28.812.4 282.8b331.6 34.8c1.5 1.5c1.7 257.5334.1
TSAT 2469b,d2635 31.72.6 33.5c,d16.8 364.3c473.6 34.8c2.0 1.4c2.0 358.7d341.6
Week 16
CHr 36063347 31.32.8 28.214.3 279.5b326.9 34.4c1.6 1.7c1.9 267.7353.2
TSAT 2629b2640 31.52.9 32.7c,d14.9 372.6c518.1 34.3c1.9 1.5c2.3 377.5d361.6
Abbreviations are: rhEPO, recombinant human erythropoietin; Hct, hematocrit; TSAT, transferrin saturation; CHr, reticulocyte hemoglobin content; RBC, red
blood cells. All results are expressed as mean  SD.
a P  0.001 compared to baseline value
b P  0.01 compared to baseline value
c P  0.0001 compared to baseline value
d P  0.05 between the two groups
Table 4. Number of patients in whom reticulocyte hemoglobinTable 3. Number of patients in whom transferrin saturation was
less than 20% and reticulocyte hemoglobin content content was less than 32.5 pg and transferrin saturation
was under 20%, or 20% or morewas under 32.5 pg, or 32.5 pg or more
TSAT 20% CHr  32.5 pg
Group CHr 32.5 pg CHr 32.5 pg Group TSAT 20% TSAT 20%
CHr (N  9) 6 (66.7%) 3 (33.4%)CHr (N  26) 6 (23.1%)a 20 (76.9%)a
TSAT (N  14) 8 (57.1%) 6 (42.9%) TSAT (N  12) 8 (66.7%) 4 (33.4%)
Abbreviations are: TSAT, transferrin saturation; CHr, reticulocyte hemoglo- Abbreviations are: TSAT, transferrin saturation; CHr, reticulocyte hemoglo-
bin content.bin content.
a P  0.043
DISCUSSIONSafety
This study demonstrates that TSAT, a marker of ironThree patients died during this study. Two patients
status at the total body level, is superior to CHr, a markerin the CHr group died; one during week 4 (bacterial
of iron status at the reticulocyte level, for treatmentpneumonia) and one during week 16 (sudden death by
of iron deficiency and reducing the amount of rhEPOunknown cause) of the trial period. One patient in the
required in Japanese chronic hemodialysis patients withTSAT group died in week 7 because of a liver tumor
iron deficiency anemia.that was not discovered at patient enrollment and ran-
So far, functional iron deficiency has been defined asdomization. One patient in the TSAT group was prema-
an impaired iron supply from body iron stores despiteturely discontinued from the study because of massive
a normal or elevated serum ferritin because of the accel-bleeding due to a femoral bone fracture and need for
erated need for iron for erythropoiesis stimulated withblood transfusion.
administered rhEPO [8, 9]. CHr was expected to be aNo differences in hospitalizations or infection rate
sensitive marker of functional iron deficiency because itwere observed. One patient in the CHr group and one
directly reflects the iron-deficient erythropoiesis at thepatient in the TSAT group were hospitalized for infec-
erythrocyte level regardless of the total body iron storestion of renal cysts and internal shunt obstruction, respec-
tively. [29–32].
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In this interventional study, increase of CHr was ob- did not increase and iron deficiency was not improved
significantly. The difference of the iron administered toserved in week 4, reflecting the change of the iron status
previous to the significant elevation of TSAT in the participants in the TSAT group may have contributed to
increasing the amount of iron stores in the bone marrow,TSAT group, which was first observed in week 13. As
reported by several authors [29–32], CHr is an excellent spleen, and liver, as well as in the erythrocytes, as indi-
cated by the increase of TSAT and serum ferritin. Theseindicator of iron status, especially to detect the change
of iron status within a short timespan and to evaluate findings are compatible with several reports that main-
taining TSAT at a high level leads to an increase of thethe efficacy of iron supplement therapy in a short time
period. Considering these results, CHr may reflect the iron stores, enhanced iron delivery to the tissues, and a
reduced amount of rhEPO required [9, 13, 19, 20].improvement of iron status more sensitively than TSAT.
Although we hypothesized that CHr reflects the func- Iron overload is a cause of the increase in cardiovascu-
lar and infectious morbidity, parenchymal iron infiltra-tional iron deficiency more efficiently, and that leads to
the reduction of the amount of rhEPO required with tion, risk of cancer, and even relative resistance to rhEPO
[5, 6, 8–10, 33], so iron supplementation should be imple-effective iron treatment, our study has disclosed that CHr
was a sensitive, but might be an insufficient, indicator for mented with careful monitoring of hematologic and iron
status markers. If hematocrit does not react to rhEPO,iron deficiency. Although two indices, CHr and hypo-
chromic red blood cells, promptly improved in both while serum ferritin progressively increases during iron
treatment, iron therapy should be suspended. However,groups after a series of intravenous iron therapy, im-
provement of the values of CHr and hypochromic red these adverse effects are reported to occur when the
serum ferritin level is more than 500 ng/mL [9, 10, 33].blood cells stopped 11 weeks after the intervention and
no more improvement was observed until the end of the Although the % CV value of TSAT or serum ferritin
was higher than CHr, and it is probable that extremetrial. On the contrary, a substantial increase of the TSAT
value and serum ferritin has been observed only in the variability of the test might lead to unnecessary treat-
ment of patients without iron deficiency, the serum ferri-TSAT group until the end of the trial, followed by the
reduction of rhEPO doses. tin and TSAT values in the TSAT group at the end of
the present study, 372.6 ng/mL and 32.7%, may be levelsIn addition, of 26 participants in the CHr group catego-
rized with iron deficiency by TSAT less than 20%, the with relatively less risk as a target of iron therapy.
The strategy of iron treatment adopted in the presentCHr value of 20 participants was 32.5 pg or more at the
end of the trial. In contrast, the proportion of patients study was significantly different from those adopted in
the United States and in Europe. We used iron colloid,who had TSAT values less than 20% in the TSAT group,
as well as CHr less than 32.5 pg, was the same as those instead of iron dextran or iron gluconate, which were
widely used in the United States and in Europe [8, 34],in the CHr group. This result indicates that the reason
why more patients in the CHr group had CHr values but were not available in Japan. The dose of iron in the
present study was also significantly lower than those usedhigher than 32.5 pg despite TSAT less than 20% is not
due to the study design, but due to the different charac- in the United States or in Europe [8, 34]. In the present
study, to avoid the risk of iron overload, we used 240ters of CHr and TSAT. When CHr was less than 32.5
pg, two thirds of the patients had TSAT less than 20%, mg of iron over 2 weeks, which was revealed to be a
sufficient dose to improve iron deficiency.but even if CHr was less than or equal to 32.5 pg, TSAT
was not always more than 20% when iron supplementa- For the present study, we defined iron deficiency as
TSAT less than 20% and set the cutoff value for induc-tion was based on CHr value. These results suggest that
the increase of CHr does not always lead to the increase tion of intravenous iron therapy as CHr less than 32.5
pg in the CHr group, considering the sensitivity andof TSAT. Although the CHr values in both groups were
almost the same, TSAT and serum ferritin were higher specificity for the diagnosis. This cutoff value is signifi-
cantly higher than the value used in the United Statesin the TSAT group, and this was because the amount of
total iron administered during the trial was 40% higher and in Europe [29–32]. With respect to Japanese chronic
hemodialysis patients, Okano et al proposed the cutoffin the TSAT group compared with the CHr group. These
results also indicate that the amount of iron administered value of CHr as 32.2 pg, considering the correlation with
TSAT, and the sensitivity and the specificity of diagnosis,to participants in the CHr group may be a minimal dose
to satisfy iron stores at a reticulocyte level, and intrave- when iron deficiency was defined as TSAT less than 20%
(Abstract, Okano et al, J Jpn Soc Dial Ther 34:1079,nous iron supplementation based on the CHr value in-
creases the iron stores only in erythrocytes and that the 2001). Harada et al proposed the cutoff value of CHr in
Japanese chronic hemodialysis patients as 32.0 pg, giventotal body iron stores remain unsatisfactory. This may
be because CHr is too sensitive and elevates rapidly to that whether the hematocrit value was improved or not
by the administration of parenteral iron was clearly de-the cutoff value before extra doses of iron to increase
body iron stores are administered. As a result, TSAT pendent on the value of CHr (i.e., iron deficiency anemia
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was improved by administration of iron when patient’s which rapidly reflects the change of iron status, but may
be insufficient as a target of iron supplementation therapy.CHr was less than 32.0 pg (personal communication). In
the present study, we set the cutoff value of CHr as 32.5
pg, which was rather higher than the values proposed ACKNOWLEDGMENTS
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